Neoadjuvant Chemotherapy in advanced Epithelial Ovarian cancer (EOC)
Effect on peri-operative negative outcomes
Versandkostenfrei!
Versandfertig in 6-10 Tagen
32,99 €
inkl. MwSt.
PAYBACK Punkte
16 °P sammeln!
Epithelial Ovarian cancer (EOC) is one of the most common malignancies in women worldwide. Most of the patients present with advanced stage disease and need extensive cytoreductive surgery to achieve optimal debulking, which is associated with increased morbidity and mortality in most of the hands. Neoadjuvant chemotherapy (NACT) has been used by many people in this setting in an effort to downstage the disease and hence decrease the magnitude of surgery and its attendant negative outcomes. This book summarizes the work done by authors to explore the effect of NACT on negative peri-operative o...
Epithelial Ovarian cancer (EOC) is one of the most common malignancies in women worldwide. Most of the patients present with advanced stage disease and need extensive cytoreductive surgery to achieve optimal debulking, which is associated with increased morbidity and mortality in most of the hands. Neoadjuvant chemotherapy (NACT) has been used by many people in this setting in an effort to downstage the disease and hence decrease the magnitude of surgery and its attendant negative outcomes. This book summarizes the work done by authors to explore the effect of NACT on negative peri-operative outcomes in advanced EOC. The data presented in this book thus sheds some light on impact of NACT on immediate post operative outcomes in patients with advanced EOC and hence will be beneficial to trainees, researchers and practising oncologists.
Andere Kunden interessierten sich für
